June 20, 2025Open Access

In‐Utero Therapy for Fetal Vascular Anomalies: Efficacy and Tolerance of Sirolimus Administered to the Pregnant Patient

Key Points

Key points are not available for this paper at this time.

Abstract

The authors declare no conflicts of interest. All data generated or analyzed during this study are included in this article. Further inquiries can be directed to the corresponding author.

Read Full Paperexternally

KI fragen

Bookmark

View Full Paper

Cite This Study

Iacobas et al. (Fri,) studied this question.

synapsesocial.com/papers/69e5faf0bde0d10efc13c5a4 https://doi.org/https://doi.org/10.1002/pd.6834

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

1How we approach the use of sirolimus and new agents: Medical therapy to treat vascular anomalies2022 · 29 citations
2Rapamycin improves TIE2-mutated venous malformation in murine model and human subjects2015 · 240 citations
3<i>In‐utero</i> treatment of large symptomatic rhabdomyoma with sirolimus2018 · 36 citations
4Oral Sirolimus: An Option in the Management of Neonates with Life-Threatening Upper Airway Lymphatic Malformations2019 · 46 citations
5Sirolimus therapy for fetal cardiac rhabdomyoma in a pregnant woman with tuberous sclerosis2019 · 60 citations

KI fragen

Bookmark

View Full Paper